Acadia Pharmaceuticals vs Pacira BioSciences
ACAD and PCRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACAD and PCRX compare
Acadia Pharmaceuticals is the larger company, worth 2.2 times as much as Pacira BioSciences ($3.2B against $1.5B).
On earnings, Acadia Pharmaceuticals is cheaper: it trades at 8.3× trailing earnings, against 104× for Pacira BioSciences.
Acadia Pharmaceuticals grew revenue faster over the last twelve months (11.8% versus 5.7% for Pacira BioSciences).
Acadia Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 33.4% compared with 2.0% at Pacira BioSciences.
Acadia Pharmaceuticals scores higher on the StockData Score (16 against 6 for Pacira BioSciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACAD | PCRX |
|---|---|---|
| Size and price | ||
| Market cap | $3.2B | $1.5B |
| Share price | $18.32 | $36.48 |
| Change, 1 year | −23.7% | 53.4% |
| Change, 5 years | −2.5% | −29.3% |
| Beta (5Y) | 0.53 | 0.12 |
| Employees | 798 | 829 |
| StockData Score | ||
| Total score | 16 (better) | 6 |
| Valuation score | 4 (better) | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 4 (better) | 3 |
| Health score | 6 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 8.3× (better) | 104× |
| P/S | 2.8× | 1.9× (better) |
| P/B | 2.4× | 2.2× (better) |
| EV/EBITDA | 25.5× | 14.9× (better) |
| P/FCF | 21.7× | 8.1× (better) |
| FCF yield | 4.6% | 12.3% (better) |
| Fair value | $25.26 | $28.47 |
| Margin of safety | 27.5% (better) | −28.1% |
| Growth | ||
| Revenue growth (TTM) | 11.8% (better) | 5.7% |
| Revenue growth, 5Y average | 19.4% (better) | 11.1% |
| Net income growth (TTM) | 71.3% | – |
| EPS growth (TTM) | 66.2% | – |
| EPS growth, 5Y average | – | −45.5% |
| Profitability | ||
| Gross margin | 91.1% (better) | 79.2% |
| Operating margin | 7.6% (better) | 2.7% |
| Net margin | 33.4% (better) | 2.0% |
| FCF margin | 12.8% | 24.1% (better) |
| Return on equity | 35.7% (better) | 2.0% |
| Return on invested capital | 42.1% (better) | 3.0% |
| Financial health | ||
| Debt / equity | 0.00 | 0.54 (better) |
| Net debt / EBITDA | – | 1.07 |
| Interest coverage | – | 1.3× |
| Current ratio | 3.39 | 5.04 (better) |
| Altman Z-score | 4.32 (better) | 2.44 |
| Piotroski F-score | 6 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | −1.5% | 10.2% (better) |
| Shareholder yield | −1.5% | 10.2% (better) |
| Ownership | ||
| Held by institutions | 97.9% | 110% |
| Held by insiders | 27.8% | 6.1% |
| Insider net buying, 12 months | −$2.5M | −$2.4M (better) |
| Short interest, % of float | 6.7% | 8.9% |
Go deeper
- ACAD stock overview
- ACAD income statement
- ACAD valuation and score
- PCRX stock overview
- PCRX income statement
- PCRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.